NIH Awards SBIR Grant to Purilogics to Develop Purexa Affinity Membrane to Improve mAb Purification Productivity - July 17 2019
Purilogics, as a pioneer in novel high-performance membrane chromatography development, has received a second Small Business Innovation Research (SBIR) grant from National Institute of General Medical Sciences this year. This new award is a SBIR Phase II grant for ~$1.5 M to develop novel, Protein A based affinity chromatographic membranes with high binding capacities. These devices are designed to enable accelerated purification speeds in monoclonal antibody (mAb) production. Monoclonal antibodies are principal components of many therapeutic regimens for chronic conditions such as cancers, autoimmune disorders, cardiovascular diseases, and many orphan diseases. With nearly 3,000 distinct programs industry-wide, mAb production continues to grow every day. The biopharmaceutical industry is moving towards high-productivity, small-batch production schemes as a strategy to combat market uncertainty associated with increasing competition and technological advancement. There are significant unmet needs in mAb production and Purilogics’ affinity membrane chromatography products will enable rapid purification that will integrate seamlessly into current production schemes and is well suited to assist in the industry shift towards continuous production.
Topics: Custom affinity membrane chromtoraphy, Continuous processing, Fast purification
About HHS SBIR program: HHS SBIR and STTR programs are an integral source of capital for early stage U.S. small businesses that are creating innovative technologies to improve health. These programs help small businesses break into the federal research and development (R&D) arena, create life-saving technologies, and stimulate economic growth. Please see details at https://sbir.nih.gov/about
The feed photo is downloaded from Dreamstime.com (Photo 91244401 © Cuteimage).